UPDATE: Halozyme Announces Temporary Halt of Phase 2 Trial Enrollment
April 04, 2014 at 08:02 AM EDT
Halozyme Therapeutics, Inc. (NASDAQ: HALO) today announced that as a result of a recommendation received yesterday from an independent ...